Ikena Oncology (IKNA) Projected to Post Quarterly Earnings on Monday

Ikena Oncology (NASDAQ:IKNA - Get Free Report) is expected to be issuing its Q1 2025 quarterly earnings data before the market opens on Monday, May 12th. Analysts expect Ikena Oncology to post earnings of ($0.21) per share for the quarter.

Ikena Oncology (NASDAQ:IKNA - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported ($0.18) earnings per share for the quarter, topping analysts' consensus estimates of ($0.21) by $0.03. On average, analysts expect Ikena Oncology to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Ikena Oncology Stock Up 5.1 %

Shares of IKNA traded up $0.06 during mid-day trading on Friday, reaching $1.14. 63,892 shares of the stock traded hands, compared to its average volume of 169,419. The firm has a market cap of $54.77 million, a price-to-earnings ratio of -0.92 and a beta of 0.47. The stock has a fifty day simple moving average of $1.23 and a 200 day simple moving average of $1.46. Ikena Oncology has a 12-month low of $0.97 and a 12-month high of $1.94.

Ikena Oncology Company Profile

Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.